Who
Steven K. Galson
Director
Company insider
Files Form 4 as: Director, BioCryst Pharmaceuticals; Director, Vanda Pharmaceuticals.
In numbers
- Trades disclosed
- 20
- Buys
- 1
- Sells
- 0
- Bought
- $120K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 1 Jul 2010
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —33,540 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —15,294 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,181 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —49,933 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —6,820 at $0.00 | filing |
| 13 May 2024filed 15 May 2024 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $120K21,940 at $5.49 | filing |
| 13 Jun 2023filed 15 Jun 2023 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,072 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —16,745 at $0.00 | filing |
| 7 Jun 2022filed 9 Jun 2022 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,022 at $0.00 | filing |
| 7 Jun 2022filed 9 Jun 2022 | BCRX BioCryst PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —12,866 at $0.00 | filing |
| 1 Sep 2021filed 2 Sep 2021 | BCRX BioCryst Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 22 May 2014filed 27 May 2014 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 20 Jun 2013filed 24 Jun 2013 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 14 Jun 2012filed 18 Jun 2012 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 16 Jun 2011filed 17 Jun 2011 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 1 Jul 2010filed 28 Jan 2011 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 1 Jul 2010filed 2 Jul 2010 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.